Close Menu

NEW YORK (GenomeWeb) – Genomics plc, an Oxford, UK-based bioinformatics company, announced today that it has inked a deal with Biogen to screen drug targets for the firm.

Genomics will use its genomic data analysis and interpretation capabilities to refine Biogen’s drug target selection. The firm's platform combines proprietary algorithms and software with its integrated genome-phenome database and analytical expertise to uncover relationships between genetic variation and human health outcomes, it said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.

The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.

Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.

In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.

Jun
17
Sponsored by
Illumina

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.